Floatz logo

ibi351

Colorectal Cancer Metastatic

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

89 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Calcium folinate pentahydrate
Ciusss de L'Est de l'Île de Montréal
Phase 4BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
Regorafenib
China Medical University, China
Phase 4BB

View all 50 →

Same molecule, other indications

ibi351 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
KRAS G12C MutationDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →